The SYK inhibitor market is poised for rapid growth, driven by increased interest in addressing unmet needs in autoimmune diseases, hematological conditions, and cancer. With ongoing clinical trials ...

The "SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2030" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Global SYK Inhibitor Market ...

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...

Hutchmed is preparing to file for approval of a drug for the rare autoimmune disorder warm antibody autoimmune haemolytic ...

In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (“ITP”). Positive results from ESLIM-01 ...

Chinese biopharma Hutchmed today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHME ...

Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic ...

Stryker Corporation (NYSE:SYK) is one of the best healthcare AI stocks to buy now. On December 11, Citi cut the price target on Stryker Corporation (NYSE:SYK) from $455 to $420, while maintaining a ...

Fintel reports that on December 19, 2025, Citizens upgraded their outlook for Stryker (NYSE:SYK) from Market Perform to Market Outperform. Analyst Price Forecast Suggests 23.42% Upside As of December ...